Jilin Province Xidian Pharmaceutical Sci-Tech Development Stock Forum

The company's low ROE and stagnant net income growth are unappealing. Despite high profit retention, the low ROE indicates that investors may not be reaping the benefits. The recent decision to pay dividends may signal a change in management's approach to shareholder returns.